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EFFECT OF A SINGLE AMINO ACID CHANGE IN MHC CLASS I MOLECULES
ON THE RATE OF PROGRESSION TO AIDS
XIAOJIANG GAO, PH.D., GEORGE W. NELSON, PH.D., PETER KARACKI, B.A., MAUREEN P. MARTIN, M.D., JOHN PHAIR, M.D.,
RICHARD KASLOW, M.D., JAMES J. GOEDERT, M.D., SUSAN BUCHBINDER, M.D., KEITH HOOTS, M.D., DAVID VLAHOV, PH.D.,
STEPHEN J. O’BRIEN, PH.D., AND MARY CARRINGTON, PH.D.

ABSTRACT
Background From studies of genetic polymorphisms and the rate of progression from human immunodeficiency virus type 1 (HIV-1) infection to the acquired immunodeficiency syndrome (AIDS), it appears
that the strongest susceptibility is conferred by the
major-histocompatibility-complex (MHC) class I type
HLA-B*35,Cw*04 allele. However, cytotoxic T-lymphocyte responses have been observed against HIV-1
epitopes presented by HLA-B*3501, the most common HLA-B*35 subtype. We examined subtypes of
HLA-B*35 in five cohorts and analyzed the relation of
structural differences between HLA-B*35 subtypes to
the risk of progression to AIDS.
Methods Genotyping of HLA class I loci was performed for 850 patients who seroconverted and had
known dates of HIV-1 infection. Survival analyses with
respect to the rate of progression to AIDS were performed to identify the effects of closely related HLAB*35 subtypes with different peptide-binding specificities.
Results HLA-B*35 subtypes were divided into two
groups according to peptide-binding specificity: the
HLA-B*35-PY group, which consists primarily of HLAB*3501 and binds epitopes with proline in position 2
and tyrosine in position 9; and the more broadly reactive HLA-B*35-Px group, which also binds epitopes
with proline in position 2 but can bind several different amino acids (not including tyrosine) in position
9. The influence of HLA-B*35 in accelerating progression to AIDS was completely attributable to HLAB*35-Px alleles, some of which differ from HLA-B*35PY alleles by only one amino acid residue.
Conclusions This analysis shows that, in patients
with HIV-1 infection, a single amino acid change in
HLA molecules has a substantial effect on the rate of
progression to AIDS. The different consequences of
HLA-B*35-PY and HLA-B*35-Px in terms of disease
progression highlight the importance of the epitope
specificities of closely related class I molecules in the
immune defense against HIV-1. (N Engl J Med 2001;
344:1668-75.)

resist a wide variety of pathogens.4,5 If this model accurately explains the diversity of class I molecules, alleles encoding functionally distinct molecules should
provide a range of protection against a given pathogen. However, accurately assigning HLA alleles or
loci to the defense against a particular infectious disease has been difficult for several reasons. Because of
the extreme polymorphism and fairly even distribution of alleles that characterize the HLA loci, studies
would require large cohorts to achieve sufficient statistical power. The effects of the genetic makeup of
the host on infectious diseases are complex and may
involve multiple loci, a fact that complicates analyses
of the influence of HLA alleles on disease. The patterns of linkage disequilibrium (the nonrandom association between two linked loci) among the many
functionally related loci in the major-histocompatibility-complex (MHC) genes also make it difficult to
identify the causative disease locus.
HLA-B*35, which almost always neighbors HLACw*04 on chromosome 6, has been the only allele
consistently associated with rapid progression to the
acquired immunodeficiency syndrome (AIDS) among
a large number of conflicting or unconfirmed associations between HLA alleles and various outcomes
in patients with human immunodeficiency virus type
1 (HIV-1).6-10 Strong evidence for an effect of HLAB*35,Cw*04 on progression to AIDS has been observed in white but not in black HIV-infected patients
for whom the date of seroconversion is known, raising the question of whether HLA-B*35 or HLACw*04 operates immunologically or, alternatively, is
simply associated with another locus that accelerates
the progression to AIDS.10 Protection against HIV-1
and simian immunodeficiency virus (SIV) has been
strongly correlated with cytotoxic-T-lymphocyte activity.11-14 The molecule encoded by HLA-B*3501,
the most common allele among HLA-B*35 subtypes,
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H

LA class I molecules present antigenic
epitopes to T lymphocytes, thereby initiating a specific immune response and the
clearance of foreign material.1-3 The genes
encoding HLA class I molecules are highly polymorphic. The great diversity of these genes appears to
have been selected over time so that mammals can
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is known to bind and present a variety of HIV-1 antigenic epitopes and to induce cytotoxic-T-lymphocyte reactivity to these epitopes.1-3 Thus, susceptibility
associated with HLA-B*35 cannot be attributed to an
inability of HLA-B*3501 to elicit cytotoxic-T-lymphocyte reactivity.
Differences in the amino acid sequences of the
HLA class I peptide-binding region have been shown
to affect the binding of peptides, particularly in the
B and F pockets of the HLA molecule, which interact with the second amino acid residue (P2) and the
carboxy-terminal amino acid residues (P9, in most
cases) of bound peptides, respectively.15 In this study,
we investigated the rate of progression to AIDS among
patients with subtypes of HLA-B*35 alleles that correlate with the peptide-binding properties of each
subtype.
METHODS
Patients
HIV-1–infected patients for whom the dates of seroconversion
were known were from five cohorts: the Multicenter AIDS Cohort
Study (MACS),16 the Multicenter Hemophilia Cohort Study
(MHCS),17 the Hemophilia Growth and Development Study
(HGDS),18 the San Francisco City Clinic Cohort (SFCC),19 and
the AIDS Linked to Intravenous Experience (ALIVE) Study.20 A
total of 592 white patients, 219 black patients, and 39 patients
from other racial groups were included in our study. Patients from
the MACS and ALIVE cohorts who seroconverted were representative of all HIV-infected patients, whereas patients from the SFCC
and MHCS cohorts showed a moderate survival bias, because biologic samples were unavailable for patients with the most rapid
rates of progression to AIDS.21
HLA Typing
For HLA typing, genomic DNA was isolated from lymphoblastoid B-cell lines or from peripheral-blood lymphocytes and amplified with a panel of 96 specific primers by the polymerase chain
reaction (PCR) for HLA-A, B, and C.22 Each reaction included
primers used as positive controls that amplified a 796-bp fragment
from the third intron of HLA-DRB1. HLA PCR products underwent electrophoresis on 1.5 percent agarose gels containing ethidium bromide, and PCR products were visualized under ultraviolet
light. More precise typing for HLA-B*35–related subtypes was performed by direct sequencing of the PCR product. 23 The sequences were analyzed with MatchTools and MT Navigator Allele Identification software (Applied Biosystems Division, Perkin–Elmer,
Foster City, Calif.).
Statistical Analysis
Survival analyses were performed separately for white and black
patients from the combined cohorts (MACS, MHCS, HGDS,
SFCC, and ALIVE) who seroconverted.16-20 Four AIDS-related
outcomes were considered end points of survival analysis: a CD4
T-lymphocyte count of less than 200 per cubic millimeter, progression to AIDS according to the 1993 definitions of the Centers for Disease Control and Prevention (CDC), 24 progression to
AIDS according to the CDC’s more restrictive 1987 definition, 25
and death from an AIDS-related cause. We performed Kaplan–
Meier and Cox model analyses using the LIFETEST and PHREG
procedures of the SAS System (SAS Institute, Cary, N.C.). Genetic factors with a confirmed effect on progression to AIDS (variant
chemokine receptor alleles CCR5∆32 and CCR2-641) were included as confounding covariates in all Cox model analyses 26,27;
overall homozygosity for HLA class I alleles was included as a
confounding covariate in some analyses, as noted.10

RESULTS
Association of HLA Class I Alleles with Progression
to AIDS

The influence of 61 individual HLA alleles (grouped
according to serologic specificities) on the rate of progression to AIDS was determined in a sample of 592
white and 219 black patients who had seroconverted
(for more information, see http://rex.nci.nih.gov/
lgd/pubs/2001.htm). HLA-B*27 showed a protective effect against progression to AIDS in whites (relative hazard of progression in those with the allele,
0.43; 95 percent confidence interval, 0.26 to 0.72;
P=0.001), as was previously predicted for this allele,28,29 and HLA-B*57 was also weakly protective
in whites (relative hazard, 0.55; 95 percent confidence
interval, 0.31 to 0.99; P=0.04), also confirming previous reports.30,31 The results also agree with the previous observation of a strong susceptibility to AIDS
in whites with the HLA-B*35 group of alleles and
HLA-Cw*04,6-10 which are the only HLA class I genotypes significantly associated with progression to
AIDS after statistical correction for multiple tests32-34
(Fig. 1).
Survival analysis of the effect of all HLA-B*35 subtypes combined indicated that the effects of HLAB*35 are codominant. The relative hazards of progression of 1.71 for patients with a single copy and
5.23 for those with two copies of any HLA-B*35 allele were significant (Fig. 1). However, no effect of the
HLA-B*35 group of alleles was observed in blacks,
although the lack of an effect of homozygosity for
HLA-B*35 in this racial group is inconclusive because the sample included only two patients who were
homozygous for HLA-B*35.
Association of HLA-B*35 Subtypes with Progression
to AIDS

Only a single subtype of HLA-Cw*04 (HLACw*0401) was present in both the white and the
black cohorts. On the other hand, five HLA-B*35
alleles were present in our patients; they encode products that vary from each other by no more than three
amino acids throughout the entire HLA molecule
(Table 1). The amino acid composition of the P2
pocket, which recognizes peptides that have proline
(P) at the second position (P2), is identical in all of
these HLA-B*35 molecules. However, the amino acid
composition of the P9 pocket varies in the different
HLA-B*35 subtypes, corresponding to variation in
amino acid preference at the carboxyl terminal of the
presented peptide.
We included the HLA-B*53 allele in our analysis
of HLA-B*35 subtypes for several reasons. First,
HLA-B*5301 is phylogenetically closely related to
the HLA-B*35 group of alleles and is probably derived from a single gene conversion within the sequence encoding the P9 pocket of an HLA-B*35 precursor.35,36 Second, HLA-B*5301 binds specifically
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Figure 1. Survival Analysis of the Effect of HLA-B*35 on AIDS-free Survival (According to the 1987 CDC Definition) in White Patients
(Panel A) and Black Patients (Panel B) from Combined Cohorts.
Patients who were heterozygous (blue curve) or homozygous (red curve) for HLA-B*35 are compared with patients who did not
carry HLA-B*35. Relative hazards and significance were calculated in Cox-model analyses, with heterozygosity and homozygosity
for HLA-B*35 considered as covariates, and with overall HLA class I homozygosity and the presence of protective genotypes of the
chemokine receptors CCR2 or CCR5 considered as confounding covariates.10,26,27

TABLE 1. VARIATIONS

HLA ALLELE

B*35-Px
B*3502
B*3503
B*3504
B*5301
Total
B*35-PY
B*3501
B*3508
Total

IN THE

PEPTIDE-BINDING SITES AND MOTIFS OF HLA-B*35 SUBTYPES DETECTED
AND THEIR EFFECT ON PROGRESSION TO AIDS.*

PEPTIDE-BINDING SITE†
77

80

81

S
—
—
N

N
—
—
I

L
—
—
A

N
D
—
D

Y
F
—
S

—
—

—
—

—
—

D
D

S
S

ANCHOR RESIDUE

114 116 156

IN

WHITE PATIENTS (N=592)

PATIENTS

WITH

AIDS

BLACK PATIENTS (N=219)

FREQUENCY

RELATIVE HAZARD

P

FREQUENCY

RELATIVE HAZARD

P

(95% CI)

VALUE

(%)

(95% CI)‡

VALUE

0.0
0.5
0.0
12.3
12.8

—
—
—
2.11 (1.13–3.95)
2.06 (1.10–3.86)

—
—
—
0.02
0.02

8.9
0.0
8.9

0.94 (0.43–2.04)
—
0.94 (0.43–2.04)

0.87
—
0.87

P2

P9

(%)

L
—
—
—

P
P
P
P
P

L/V
M/L
L/V
None
X§

1.3
2.2
0.1
0.8
4.4

2.90
2.70
0.0
1.70
2.65

—
R

P
P
P

Y
Y
Y

4.3
0.4
4.7

1.22 (0.80–1.88)
2.22 (0.70–7.03)
1.30 (0.87–1.95)

(1.57–5.37) <0.001
(1.70–4.30) <0.001
0.87
(0.68–4.23)
0.25
(1.84–3.82) <0.001
0.36
0.17
0.20

*A dominant model was used, in which the rate of progression to AIDS (according to the 1987 definition of the CDC) in patients carrying one or two
copies of the HLA allele was compared with that in patients without that allele. CI denotes confidence interval. Relative hazards, significance, and confidence
intervals were calculated with the use of the Cox model, with overall class I homozygosity and the presence of protective genotypes of the chemokine
receptors CCR2 and CCR5 considered confounding covariates.10,26,27
†Numbers indicate amino acid positions. Dashes indicate identity with the sequence listed for B*3502.
‡The relative hazard for B*3503 was not calculated, but this allele was included in the total for P*35-Px.
§X indicates a preference at the P9 pocket for a hydrophobic amino acid other than tyrosine or no clear preference.
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to proline at P2 and nonspecifically at the carboxyterminal (P9) site; these specificities are similar but
not identical to those of other HLA-B*35 subtypes
(Table 1). Third, black participants carrying one or
two copies of the HLA-B*53 allele, in whom HLAB*5301 has a relatively high frequency (12.3 percent), showed a significant predisposition to rapid
progression to AIDS (relative hazard, 2.11; 95 percent confidence interval, 1.13 to 3.95; P=0.02).
The HLA-B*35 and B*53 subtypes fall into two
general groups on the basis of peptide-binding preference: those that bind peptides containing proline
at the P2 position but that show no preference for a
specific amino acid at P9, which are termed the HLAB*35-Px group (P indicates proline and x indicates no
single preference; the group includes HLA-B*3502,
B*3503, B*3504, and B*5301); and those that bind
peptides containing proline at P2 and tyrosine at P9,
which are termed the HLA-B*35-PY group (P indi-

Whites (N=559)

A

cates proline and Y indicates tyrosine; the group includes HLA-B*3501 and B*3508) (Table 1). Survival
analyses with respect to the progression to AIDS (according to the 1987 definition of the CDC)24 were
performed individually for all HLA-B*35 subtypes
(plus HLA-B*5301) to test whether variability among
subtypes might affect the rate of progression to AIDS
(Table 1).
A striking observation was that HLA-B*3501, the
most common of the HLA-B*35 subtypes, had no
effect on disease progression in either racial group
(P>0.3) (Table 1). The effect of HLA-B*35 on progression to AIDS in whites (Fig. 1A) can be attributed entirely to two subtypes, HLA-B*3502 and
B*3503, both of which are significantly associated
with rapid progression to AIDS (relative hazard
for HLA-B*3502, 2.90; relative hazard for HLAB*3503, 2.70; P<0.001 for both) (Table 1), even
though these two subtypes differ from HLA-B*3501
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Figure 2. Survival Analysis of the Effect of HLA-B*35 Subtypes on AIDS-free Survival (According to the 1987 CDC Definition) in
Patients with One Copy of an HLA-B*35-PY Allele (B*3501 or B*3508) (Blue Curve) as Compared with Patients with One Copy of an
HLA-B*35-Px Allele (B*3502, B*3503, B*3504, or B*5301) (Red Curve) and Patients with No HLA-B*35 or HLA-B*53 Alleles (Black Curve).
Only patients who were heterozygous for HLA-B were considered in the analysis, to exclude the strong, documented AIDS-accelerating effect of homozygosity at HLA-A, B, and C alleles.10 The subjects were whites (Panel A) and blacks (Panel B) from combined
cohorts who seroconverted. Relative hazards and significance are given for separate Cox-model analyses comparing each group
with all other subjects in the analysis, with homozygosity at HLA-A or C and the presence of protective genotypes of the chemokine
receptors CCR2 or CCR5 considered as confounding covariates.10,26,27 The pie charts show the allelic frequencies for all patients who
seroconverted in the two groups.
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by only one or two residues in the peptide-binding
region.37,38 Furthermore, HLA-B*5301 was significantly associated with progression to AIDS in blacks
(relative hazard, 2.11; P=0.02) and tends to be associated with susceptibility to progression to AIDS
in whites (relative hazard, 1.70), although this trend
falls short of significance (P=0.25). The predominance of HLA-B*3501 (which has no influence on
progression to AIDS), as compared with all other
HLA-B*35 alleles in blacks (Fig. 2), probably accounts
for our failure to detect an effect of HLA-B*3501
on susceptibility in this racial group (blue vs. black
curves in Fig. 1B).
Survival analysis involving four HLA-B*35-Px alleles combined (HLA-B*3502, B*3503, B*5301,
and B*3504), as compared with two B*35-PY alleles (HLA-B*3501 and B*3508), was performed to
assess the overall effect of shared attributes of peptide recognition on the progression to AIDS (Fig.
2). Only patients who were heterozygous for HLAB were considered, to exclude the strong influence
of homozygosity on progression to AIDS.10 The results demonstrate a significant association with progression to AIDS in patients who had an HLA-B*35Px allele (P<0.001 for whites, P=0.02 for blacks).
On the other hand, there was no apparent difference
in the rate of progression between patients with an
HLA-B*35-PY allele and those without an HLAB*35 allele. Furthermore, among whites, the relative
hazard of 2.69 that was determined for HLA-B*35Px (Fig. 2A) was greater than that for HLA-B*35 as
a whole (relative hazard, 1.71) (Fig. 1), since the over-

all HLA-B*35 signal in Figure 1 is diminished by the
inclusion of the patients with HLA-B*35-PY.
We calculated relative hazards for the two HLAB*35 groupings, HLA-B*35-Px and HLA-B*35-PY,
for the various AIDS-defining end points 24,25 (Table
2). Relative hazards were most significant with the
use of a dominant model (including homozygotes and
heterozygotes for a given allele in a single group),
and P values were more significant for the later outcomes (particularly AIDS according to the 1987 CDC
definition) in both white and black patients carrying
HLA-B*35-Px alleles, although an effect of these alleles was evident even in whites with CD4 cell counts
of less than 200 per cubic millimeter, an early end
point. The epidemiologic association of the HLAB*35-Px subtypes with progression to AIDS as compared with the HLA-B*35-PY subtypes is consistent
with the notion that the shared attributes of peptide
recognition of the HLA-B*35-Px alleles provide the
functional explanation for rapid progression to AIDS
in heterozygotes.
Association of HLA-Cw*04 with Progression to AIDS

The differential association of the HLA-B*35-PY
and the HLA-B*35-Px groups of alleles with progression to AIDS led us to reexamine the previously
observed association of HLA-Cw*04 with progression to AIDS.10 Three of our observations point to
the conclusion that most, if not all, of the association of HLA-Cw*04 with rapid progression is due
to its linkage disequilibrium with HLA-B*35-Px alleles. First, all patients who were heterozygous for

TABLE 2. EFFECT OF GENOTYPES INCLUDING HLA-B*35-PX AND HLA-B*35-PY
ON PROGRESSION TO FOUR AIDS-RELATED END POINTS.*

AIDS-RELATED END POINT

Whites
CD4 cell count <200
AIDS (1993)†
AIDS (1987)‡
Death
Blacks
CD4 cell count <200
AIDS (1993)†
AIDS (1987)‡
Death
All racial groups
CD4 cell count <200
AIDS (1993)†
AIDS (1987)‡
Death

NO. OF
PATIENTS

HLA-B*35-PX

HLA-B*35-PY

RELATIVE HAZARD

P

RELATIVE HAZARD

P

(95% CI)

VALUE

(95% CI)

VALUE

562
1.77
1.94
2.69
2.51

(1.23–2.55)
(1.39–2.71)
(1.86–3.88)
(1.72–3.65)

0.002
<0.001
<0.001
<0.001

0.73
0.90
1.08
1.32

(0.47–1.13)
(0.62–1.31)
(0.69–1.69)
(0.86–2.02)

0.16
0.59
0.73
0.20

1.23
1.40
2.13
1.94

(0.72–2.09)
(0.87–2.23)
(1.12–4.04)
(0.85–4.40)

0.45
0.16
0.02
0.11

1.51
1.34
0.75
1.17

(0.81–2.28)
(0.75–2.38)
(0.29–1.93)
(0.39–3.45)

0.19
0.32
0.55
0.78

1.59
1.77
2.37
2.25

(1.19–2.14)
(1.35–2.31)
(1.73–3.25)
(1.60–3.16)

0.002
<0.001
<0.001
<0.001

0.92
1.02
1.11
1.40

(0.65–1.23)
(0.75–1.38)
(0.76–1.63)
(0.96–2.05)

0.63
0.91
0.60
0.88

211

810

*Relative hazards, significance, and confidence intervals (CI) were calculated for a dominant model
as described in Figure 2.
†AIDS was defined according to the 1993 criteria of the CDC.
‡AIDS was defined according to the 1987 criteria of the CDC.
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Figure 3. Model of the Difference in the Rate of Progression to AIDS between Patients with HLA-B*35-Px and Those with HLA-B*35-PY.
HIV-1 replicates in the infected cells, and some viral protein is degraded into small peptides. The viral peptides, typically nine amino
acids in length (P1 to P9), are bound by HLA class I molecules that have appropriate P2- and P9-anchoring pockets, and these complexes are expressed on the cell surface. Amino acids forming the P2-anchoring pockets of the HLA-B*35-PY and HLA-B*35-Px molecules are identical, and both pockets have a preference for proline (P) in the P2 position of the bound peptide. However, minor
differences in the P9 pockets lead to distinct binding preferences for the carboxy-terminal amino acid of the peptides. The
HLA-B*35-PY molecules (HLA-B*3501 and B*3508) have a preference for tyrosine (Y) at the carboxy terminal of the peptide (P9),
whereas the HLA-B*35-Px molecules (HLA-B*3502, B*3503, B*3504, and B*5301) do not have a single clear preference at P9 (x) and
do not bind peptides that have tyrosine at the carboxy terminal. T-cell receptors recognize distinct HIV-1 peptides bound by specific
class I molecules expressed by the virally infected target cell. A poor or inappropriate cytotoxic-T-lymphocyte response occurs in
patients with HLA-B*35-Px, as is suggested by the rapid progression to AIDS in these patients, whereas a relatively protective response occurs in patients with HLA-B*35-PY that corresponds with the slower progression to disease in these patients.

HLA-B*3501 in our cohorts were also positive for
HLA-Cw*04, and rapid progression to AIDS is not
associated with this haplotype in white or black heterozygotes (blue line in Fig. 2). Second, patients with
HLA-Cw*04 but without HLA-B*35-Px subtype
alleles are indistinguishable from those without HLA-

Cw*04 in terms of the rate of progression to AIDS
(further information is available at http://rex.nci.
nih.gov/lgd/pubs/2001.htm). Third, in three of four
whites who were heterozygous for HLA-B*35-Px
but who did not have HLA-Cw*04, progression to
AIDS occurred very rapidly (less than five years after
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seroconversion). Thus, the differences in the rate of
progression to AIDS between the HLA- B*35-Px
and HLA-B*35-PY allele groups indicate that the
previously observed HLA-Cw*04 effect is predominantly, if not totally, due to linkage disequilibrium
with HLA-B*35-Px.
DISCUSSION

The use of large, clinically well-defined cohorts in
this study has allowed the identification of specific
subtypes of HLA-B*35 as responsible for the previously reported association between HLA-B*35 and
rapid progression to AIDS. The most common HLAB*35 subtype allele, HLA-B*3501, has little or no
effect on progression to AIDS in either white or black
patients. The finding that specific HLA-B*35-Px subtypes have similar effects in blacks and whites strongly supports the hypothesis that these HLA-B alleles
exert an effect on the immune response to HIV-1
disease.
Peptide-binding assays have shown that amino acid
substitution in the heavy chain at positions 114 (HLAB*3502) and 116 (HLA-B*3502 and B*3503) abolished the ability of the P9 pocket of HLA-B*3501
to bind tyrosine at the carboxy-terminal anchor.39 The
relatively shallow P9 pockets of HLA-B*3502 and
B*3503 do not bind tyrosine but preferentially accommodate smaller hydrophobic residues such as methionine, valine, or leucine.39 The P9 pocket of HLAB*5301 is unable to accommodate tyrosine as well,
and it appears to have no preference for a specific
amino acid.40 We suggest that the difference in affinity for tyrosine at the carboxy-terminal position of
the peptide may be the critical distinction between
HLA-B*35-Px and HLA-B*35-PY. This difference
may influence the relative efficiency of HLA-B*35Px and HLA-B*35-PY in presenting specific HIV-1
epitopes to cytotoxic T lymphocytes and may thereby account for the different effects on progression to
AIDS (Fig. 3).
We have previously shown a strong effect of HLA
class I homozygosity on susceptibility to progression
to AIDS; this effect appeared to be additive, in that
homozygosity at two or three loci had stronger effects than homozygosity at a single locus.10 We could
not assess whether homozygosity for HLA-B*35-Px
would cause even faster progression to AIDS than
heterozygosity for this group, since only two patients
homozygous for HLA-B*35-Px alleles were identified among the white patients who seroconverted.
However, the total group of HLA-B*35 alleles had
a codominant effect in whites (Fig. 1), in whom homozygosity for any combination of HLA-B*35 alleles (in six study participants) was associated with
significantly more rapid progression to AIDS than
having a single copy of the HLA-B*35-Px alleles. Because the effect of homozygosity for any combination of HLA-B*35 alleles was so severe, it may be

possible that HLA-B*35 alleles as a group, including
HLA-B*3501, have a recessive effect on susceptibility to progression to AIDS. However, five of the six
patients who had any combination of two HLAB*35 subtypes were also homozygous at the HLAC locus (HLA-Cw*0401,Cw*0401), and the single
homozygote for HLA-B*3501 in this group was homozygous at all three class I loci. Perhaps the most
parsimonious explanation for the extremely rapid
progression to AIDS in the HLA-B*35 “homozygotes” is that all harbor at least two negative genotypes — namely, at least one copy of the HLAB*35-Px group of alleles plus homozygosity at the
HLA-C locus.
Given the strength of the genetic effect described
for HLA-B*35-Px, an aggressive therapeutic regimen may be advisable for patients who are positive
for these alleles (particularly for those newly infected
with the virus). A test specifically designed to detect
the presence or absence of HLA-B*35-Px alleles
could easily be developed and would be sufficient in
terms of HLA typing, since only this set of alleles
among all other HLA types has a strong influence
on progression to AIDS. Functional studies designed
to characterize cytotoxic-T-lymphocyte activity in
HIV-1–positive patients carrying HLA-B*35-Px may
provide a deeper understanding of the mechanisms
involved in susceptibility to HIV-1 disease and may
enhance the efficacy of vaccines against HIV, drug
treatment, or both in these patients.
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